Skip to main content

藥師週刊第1655期 - 藥物警訊


資料提供:台大醫院藥劑部 Brand Dietary Supplements - Sold on Internet
Audience: Consumers and FDA notified healthcare professionals and patients of a nationwide and international recall of all lots and expiration dates of 65 dietary supplement products that were sold through the Company's website,
FDA believes that the recalled products contain the following ingredients that are currently classified, or the FDA believes should be classified, as steroids: "Superdrol," "Madol," "Tren," "Androstenedione," and/or "Turinabol." Acute liver injury is known to be a possible harmful effect of using steroid-containing products. In addition, steroids may cause other serious long-term adverse health consequences in men, women, and children. These include shrinkage of the testes and male infertility, masculinization of women, breast enlargement in males, short stature in children, a higher predilection to misuse other drugs and alcohol, adverse effects on blood lipid levels, and increased risk of heart attack, stroke, and death.
Customers who have any of the products in their possession should stop using them immediately and contact their physician if they have experienced any problems that may be related to taking one or more of the ingredients listed above. Any adverse events that may be related to use should be reported to the FDA's MedWatch Safety Information and Adverse Event Reporting Program online [at], by phone 1-800-332-1088, or by returning the postage-paid FDA form 3500 [which may be downloaded from the MedWatch "Download Forms" page] by mail [to address on the pre-addressed form] or fax [1-800-FDA-0178].
Read the complete MedWatch 2009 Safety summary, including a link to the firm press release, at:

FDA認為這些回收的產品含有下列成分: "Superdrol"、"Madol"、"Tren"、"Androstenedione" 和/或 "Turinabol" 這些成分最近被分類或FDA認為應該被分類為似類固醇的成分。使用含有類固醇的藥品可能會造成急性肝臟損傷。此外,類固醇可能會嚴重且長期的危害男性、女性和小孩的健康。其包括睪丸萎縮變小和男性不孕症、女生男性化、男性女乳化、小孩身材矮小、易濫用藥物和酒精、不利於血脂值及增加心臟病發作、中風和死亡的風險。
持有任何此類藥品的消費者應該立即停止使用,且如有因服用上述成分而發生任何相關不適之問題,應與醫師聯繫。任何與使用這些藥品相關的不良反應事件可以電話、傳真或線上通報(網址為至FDA's MedWatch Safety Information和Adverse Event Reporting Program,也可下載FDA不良反應通報表回郵寄回。